RA101495: Phase I started

Ra began a double-blind, placebo-controlled, dose-escalation, Australian Phase I trial to evaluate single doses of 0.05, 0.1, 0.2, 0.4 and 0.8 mg/kg subcutaneous RA101495 in 28 healthy volunteers. ...